STRENSIQ
Biological
Alexion Pharmaceuticals, Inc.
Total Payments
$2.9M
Transactions
18,624
Doctors
7,481
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $1.3M | 7,370 | 4,006 |
| 2023 | $1.1M | 6,384 | 3,681 |
| 2022 | $494,301 | 4,870 | 2,930 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.6M | 109 | 55.3% |
| Food and Beverage | $441,768 | 17,665 | 15.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $423,035 | 260 | 14.5% |
| Consulting Fee | $258,018 | 154 | 8.9% |
| Travel and Lodging | $112,426 | 399 | 3.9% |
| Space rental or facility fees (teaching hospital only) | $68,850 | 36 | 2.4% |
| Education | $10.00 | 1 | 0.0% |
Payments by Type
Research
$1.6M
109 transactions
General
$1.3M
18,515 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| An Observational, Longitudinal, Prospective, Long term Registry of Patients with Hypophosphatasia | Alexion Pharmaceuticals, Inc. | $1.4M | 0 |
| A Prospective Observational Sub Study of the Global Hypophosphatasia Registry to Evaluate the Potential Risk of Immune Mediated Loss of Pharmacological Effect of Asfotase Alfa in Participants with Hypophosphatasia. | Alexion Pharmaceuticals, Inc. | $206,233 | 0 |
| An Interventional, Prospective Open Label Study of Immunosuppressive Therapies (ISTs) to Mitigate Immune Mediated Loss of Therapeutic Response to Asfotase Alfa (Strensiq) for Hypophosphatasia (RESTORE) | Alexion Pharmaceuticals, Inc. | $45,350 | 0 |
Top Doctors Receiving Payments for STRENSIQ — Page 300
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , APRN, FNP-C | Adult Health | Palm Bay, FL | $10.53 | 1 |
| , MD | Pediatric Nephrology | Knoxville, TN | $10.05 | 1 |
| , MD | Pediatric Nephrology | Knoxville, TN | $10.05 | 1 |
| , MD | Internal Medicine | Palm Beach Gardens, FL | $8.54 | 1 |
| , PA-C | Physician Assistant | Milwaukee, WI | $6.71 | 1 |
| , M.D | Neurology with Special Qualifications in Child Neurology | Greenbrae, CA | $6.32 | 1 |
| , D.O | Family Medicine | Savannah, GA | $6.11 | 1 |
Ad
Manufacturing Companies
- Alexion Pharmaceuticals, Inc. $2.9M
- AstraZeneca Pharmaceuticals LP $725.00
Product Information
- Type Biological
- Total Payments $2.9M
- Total Doctors 7,481
- Transactions 18,624
About STRENSIQ
STRENSIQ is a biological associated with $2.9M in payments to 7,481 healthcare providers, recorded across 18,624 transactions in the CMS Open Payments database. The primary manufacturer is Alexion Pharmaceuticals, Inc..
Payment data is available from 2022 to 2024. In 2024, $1.3M was paid across 7,370 transactions to 4,006 doctors.
The most common payment nature for STRENSIQ is "Unspecified" ($1.6M, 55.3% of total).
STRENSIQ is associated with 3 research studies, including "An Observational, Longitudinal, Prospective, Long term Registry of Patients with Hypophosphatasia" ($1.4M).